Moderna and Immatics Announce Strategic Multi-Platform Collaboration to Develop Innovative Oncology Therapeutics
Collaboration combines leading technologies to develop breakthrough, mRNA-enabled in vivo expressed TCER® molecules Comp…
Collaboration combines leading technologies to develop breakthrough, mRNA-enabled in vivo expressed TCER® molecules Comp…
Clinical study demonstrates proof-of-concept for active personalized immunotherapy approach in a pioneering multi-center…
The prospect of an actively personalized approach to the treatment of glioblastoma has moved a step closer with the rece…
. - Regulatory authority approves clinical trial for Glioma Actively Personalized Vaccine Consortium (GAPVAC) - First…
. - Projekt wird gemeinsam von den Biotechnologiefirmen immatics (Tübingen) und BioNTech (Mainz) geleitet - Regulator…
immatics biotechnologies GmbH, a clinical-stage biopharmaceutical company leading the development of advanced immunother…
immatics biotechnologies GmbH, together with its collaborators Cancer Research UK and Cancer Research Technology today a…
immatics biotechnologies GmbH and Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced a strategic research and developmen…
. - immatics' lead cancer vaccine IMA901 to report interim phase 3 data in 2014 and final data in 2015 - Funding secur…
. - immatics' erwartet für seinen führenden Impfstoff IMA901 in 2014 erste Interimsdaten der Phase 3-Zulassungsstudie u…